Compare GPC & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPC | MDGL |
|---|---|---|
| Founded | 1928 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 12.0B |
| IPO Year | 1994 | 2005 |
| Metric | GPC | MDGL |
|---|---|---|
| Price | $103.47 | $546.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $145.67 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 2.1M | 335.0K |
| Earning Date | 04-21-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $24,300,141,000.00 | $180,133,000.00 |
| Revenue This Year | $5.46 | $58.28 |
| Revenue Next Year | $3.80 | $46.80 |
| P/E Ratio | $219.98 | ★ N/A |
| Revenue Growth | ★ 3.46 | N/A |
| 52 Week Low | $96.08 | $265.00 |
| 52 Week High | $151.57 | $615.00 |
| Indicator | GPC | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 36.88 | 74.28 |
| Support Level | $96.08 | $535.33 |
| Resistance Level | $106.48 | $572.20 |
| Average True Range (ATR) | 2.71 | 26.99 |
| MACD | 1.20 | 11.83 |
| Stochastic Oscillator | 70.92 | 82.48 |
Genuine Parts sells aftermarket automotive parts (60% of sales) and industrial products (40% of sales) in the United States and internationally. The automotive segment primarily acts as a distributor to its network of 9,800 global retail locations, of which about two-thirds are independently owned and operated. We estimate Genuine serves around 6,000 retail locations in the US operating under the Napa Auto Parts brand, with about 80% of end-market sales derived from professional customers. Its industrial segment, primarily operating under the Motion name in the United States, is a leading distributor of bearings, power transmission, and other industrial products to more than 200,000 maintenance, repair, and original equipment manufacturer customers.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.